Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis
2019 · Molecular Therapy · 121 citations
https://doi.org/10.1016/j.ymthe.2019.09.008
Y
Yanyong Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
1.3K
Citations
21
h-index
34
i10-index
Yanyong Xu is an academic researcher from Shanghai Medical College of Fudan University. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Cholesterol and Lipid Metabolism & Adipokines, Inflammation, and Metabolic Diseases. The author has an h-index of 21, co-authored 46 publications.
ORCID: 0000-0002-2811-0725Papers by this author
worksHepatic overexpression of methionine sulfoxide reductase A reduces atherosclerosis in apolipoprotein E-deficient mice
2015 · Journal of Lipid Research · 28 citations
https://doi.org/10.1194/jlr.m058776
Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr −/− mice
2017 · Scientific Reports · 25 citations
https://doi.org/10.1038/s41598-017-18232-x
Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice
2018 · Journal of Translational Medicine · 18 citations
https://doi.org/10.1186/s12967-018-1502-y
Hepatic FOXA3 overexpression prevents Western diet–induced obesity and MASH through TGR5
2024 · Journal of Lipid Research · 8 citations
https://doi.org/10.1016/j.jlr.2024.100527
Hepatic activating transcription factor 3 protects against systemic inflammation by attenuating lipotoxicity
2025 · Metabolism Open · 0 citations
https://doi.org/10.1016/j.metop.2025.100417
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat